1. Home
  2. EVC vs FHTX Comparison

EVC vs FHTX Comparison

Compare EVC & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entravision Communications Corporation

EVC

Entravision Communications Corporation

HOLD

Current Price

$2.73

Market Cap

233.8M

Sector

Industrials

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$4.36

Market Cap

246.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVC
FHTX
Founded
1996
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.8M
246.6M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
EVC
FHTX
Price
$2.73
$4.36
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$11.86
AVG Volume (30 Days)
335.2K
196.2K
Earning Date
11-04-2025
11-05-2025
Dividend Yield
7.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$420,178,000.00
$24,518,000.00
Revenue This Year
$64.06
$47.50
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.96
N/A
52 Week Low
$1.58
$2.95
52 Week High
$3.15
$7.42

Technical Indicators

Market Signals
Indicator
EVC
FHTX
Relative Strength Index (RSI) 56.75 47.16
Support Level $2.75 $4.27
Resistance Level $2.85 $4.87
Average True Range (ATR) 0.11 0.38
MACD -0.02 -0.03
Stochastic Oscillator 60.94 7.77

Price Performance

Historical Comparison
EVC
FHTX

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: